公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20140220055A1

公开(公告)日：2014-08-07

申请号：US14166932

申请日：2014-01-29

Applicant: OSAKA UNIVERSITY ,  NITTO DENKO CORPORATION

Inventor： Katsuyuki OKUBO ,  Yoshiki MAEDA ,  Arimichi OKAZAKI ,  Daisuke ASARI ,  Takuya SHISHIDO ,  Mitsuhiko HORI ,  Haruo SUGIYAMA

IPC: A61K9/00 ,  A61K38/10 ,  A61K39/00

CPC classification number: A61K9/0014 ,  A61K38/10 ,  A61K39/0011 ,  A61K2039/54

Abstract: The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

Abstract translation: 本发明提供一种用于诱导细胞免疫的透皮给药的癌症疫苗组合物，其包含（i）WT1肽和/或修饰的WT1肽; 和（ii）细胞免疫诱导启动子。 组合物有效地诱导受试者中针对癌症的细胞免疫。

公开(公告)号：US20140220105A1

公开(公告)日：2014-08-07

申请号：US14166954

申请日：2014-01-29

Applicant: Osaka University ,  NITTO DENKO CORPORATION

Inventor： Yoshiki MAEDA ,  Katsuyuki OKUBO ,  Daisuke ASARI ,  Arimichi OKAZAKI ,  Takuya SHISHIDO ,  Mitsuhiko HORI ,  Haruo SUGIYAMA

IPC: A61K39/00 ,  A61K9/70

CPC classification number: A61K39/0011 ,  A61K9/7023 ,  A61K2039/54

Abstract: The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.

Abstract translation: 本发明提供用于诱导细胞免疫的癌症疫苗胶带制剂，其包含：载体，包含设置在载体一侧的粘合剂的粘合剂层，其中所述粘合剂层携带以下组合：（i）WT1肽和/ 或修饰的WT1肽; 和（ii）第一细胞免疫诱导启动子。 胶带制剂可以提供高效率。

公开(公告)号：US20140220059A1

公开(公告)日：2014-08-07

申请号：US14166970

申请日：2014-01-29

Applicant: OSAKA UNIVERSITY ,  NITTO DENKO CORPORATION

Inventor： Daisuke ASARI ,  Kyohei MATSUSHITA ,  Arimichi OKAZAKI ,  Yoshiki MAEDA ,  Katsuyuki OKUBO ,  Mitsuhiko HORI ,  Haruo SUGIYAMA

IPC: A61K39/00 ,  A61K9/00

CPC classification number: A61K39/0011 ,  A61K9/0043 ,  A61K9/006 ,  A61K2039/541 ,  A61K2039/542

Abstract: The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

Abstract translation: 本发明提供用于诱导细胞免疫的粘膜给药用癌症疫苗组合物，其包含（i）WT1肽和/或修饰的WT1肽; 和（ii）细胞免疫诱导启动子。 组合物有效地诱导受试者中针对癌症的细胞免疫。

公开(公告)号：US20170369841A1

公开(公告)日：2017-12-28

申请号：US15537927

申请日：2015-12-22

Applicant: OSAKA UNIVERSITY

Inventor： Haruo SUGIYAMA ,  Fumihiro FUJIKI

IPC: C12N5/0783 ,  A61K39/00 ,  C12N15/113 ,  A61K39/39

CPC classification number: C12N5/0637 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/55 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/55511 ,  A61K2039/572 ,  C12N5/0638 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2501/71 ,  C12N2501/999

Abstract: Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.

公开(公告)号：US20220064287A1

公开(公告)日：2022-03-03

申请号：US17527681

申请日：2021-11-16

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US20190284228A1

公开(公告)日：2019-09-19

申请号：US16347337

申请日：2017-11-08

Applicant: OSAKA UNIVERSITY ,  KNC LABORATORIES CO., LTD.

Inventor： Haruo SUGIYAMA ,  Fumihiro FUJIKI ,  Masahiro NEYA ,  Shinya KOHNO

IPC: C07J63/00 ,  C12N5/0783 ,  A61P35/00 ,  A61K31/215 ,  A61K31/216 ,  A61K31/40 ,  A61K31/445 ,  A61K31/27 ,  A61K31/265 ,  A61K31/16 ,  A61K31/166 ,  A61K31/196 ,  A61K31/5375

Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).

公开(公告)号：US20200283533A1

公开(公告)日：2020-09-10

申请号：US16808451

申请日：2020-03-04

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230216A1

公开(公告)日：2018-08-16

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N15/09 ,  C12N5/10

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/10 ,  C12N15/09

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230212A1

公开(公告)日：2018-08-16

申请号：US15751717

申请日：2016-08-09

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/62 ,  C07K19/00

CPC classification number: C07K16/28 ,  A61K38/1709 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K16/3061 ,  C07K19/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/62

Abstract: Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.